Data alert

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge. Advances in vascular biology have enhanced our understanding of the biochemical and physiological processes by which hypertension and dyslipidemia, the two most common risk factors for CV disease,1 interact in a synergistic manner to increase
CV risk.2-4 The critical challenge is to implement this knowledge.

References are listed at the end of the Data Alert.

Synergistic actions of hypertension and dyslipidemia on endothelial function

Download 04DA-Multiple-Risk.ppt (6 slides - 0.2MB)

Synergistic actions of hypertension and dyslipidemia on endothelial function High prevalence of multiple CV risk factorsin hypertensive adults Prevalence of hypertension and dyslipidemiaincreases with age Dyslipidemia in hypertensive adults: High prevalence, insufficient treatment Number of antihypertensive agents neededto achieve systolic BP control Gemini: LDL-C and BP goal achievementby multiple-risk patients
Data_Alert.pdf (0.4MB)Data_Alert.pdf (0.4MB)


Related at vwbg.org

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide.

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.

Core Curriculum

Leading the Way in Cardiovascular Regenerative Medicine

View/Download individual slides (54 Slides)
More related